louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06783296: Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension
Official title: Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension: the STOP Study a Multicenter, Randomized, Sham-controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Hypertension
Renal Denervation Therapy
Lead sponsor: Shanghai 10th People's Hospital
Sponsor class: OTHER
First posted: 2025-01-20
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate the efficacy and safety of renal denervation (RDN) in patients with isolated diastolic hypertension (IDH). The randomized, sham-controlled, multicenter clinical trial will recruit 44 participants (33 in the treatment group and 11 in the sham control group) to assess changes in blood pressure and adverse events over a 6-month follow-up period. The study is expected to provide new evidence for the use of RDN as a treatment for IDH.


Eligibility criteria: Inclusion Criteria:

- 1. Age 18-45 years. 2. Diagnosed with isolated diastolic hypertension (office SBP \< 140 mmHg and DBP ≥ 90 mmHg without antihypertensive medication).

3. Signed informed consent.

Exclusion Criteria:

* 1. Office DBP ≥ 110 mmHg. 2. Secondary hypertension or arrhythmias affecting blood pressure accuracy (e.g., atrial fibrillation).

  3. Comorbidities such as diabetes, chronic kidney disease (eGFR \< 30 mL/min/1.73m²), coronary artery disease, or heart failure.

  4. History of stroke or myocardial infarction. 5. Known bleeding disorders or inability to tolerate anticoagulation. 6. Renal artery abnormalities or prior renal artery/coronary artery interventions.

  7. Pregnancy, breastfeeding, or planning to become pregnant. 8. Life expectancy \< 1 year. 9. Participation in another clinical trial.

Primary outcomes:
measure: Change in office diastolic blood pressure (DBP)
timeFrame: 3 months after intervention
Secondary outcomes:
measure: Change in office systolic blood pressure (SBP)
timeFrame: 3 months after intervention
measure: Change in 24-hour ambulatory blood pressure monitoring
timeFrame: 3 months after intervention
measure: Change in home blood pressure monitoring
timeFrame: 3 months after intervention
measure: control rate
timeFrame: 6 months after intervention
measure: Percentage of patients not requiring medication
timeFrame: 3 and 6 months after intervention
measure: Incidence of major adverse events
timeFrame: 6 months after intervention
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Department of Cardiology, Shanghai Tenth People's Hospital
state: Shanghai
city: Shanghai
country: China
facility: Shanghai Tenth People's Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT02150096: Laser and Therapeutic Ultrasound in the Management of the Chronic Non-specific Low Back Pain
Official title: Laser and and Ultrasound Effect on Pain and Disability in Women With Chronic Non-specific Low Back Pain: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Low Back Pain
Keywords: chronic non-specific low back pain
clinical trial
disability
women
Lead sponsor: University of Sao Paulo General Hospital
Sponsor class: OTHER
First posted: 2014-05-29
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is evaluate the laser and ultrasound effect on pain and disability in women with non-specific chronic low back pain.


Eligibility criteria: Inclusion Criteria:

* non-specific chronic low back pain
* moderate pain
* eutrophics women

Exclusion Criteria:

* disk herniation
* cardiac diseases
* psychiatrics diseases
* endocrinous diseases
* fractures of the spine
* fractures of lower members
* diabetics
* dental emergency
* local infections
* local non sensibility
* analgesics and anti-inflammatories in use
* neurologic diseases
* pregnancy

Primary outcomes:
measure: Pain evaluation
timeFrame: The pain will be evaluate before and after 25 days of the treatment
Secondary outcomes:
measure: Disability evaluation
timeFrame: The disability will be evaluate before and after 25 days of the treatment
Other outcomes:
measure: Multidimensional evaluation of pain
timeFrame: The multidimensional evaluation of pain will be realized before and after 25 days of the treatment
Locations:
city: Porto Velho
country: Brazil
facility: Sâo Lucas College
state: Rondônia
Study officials:
affiliation: SÃO PAULO UNIVERSITY
name: ANA PAULA RUBIRA, MASTER
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rubira APFA, Rubira MC, Rubira LA, Comachio J, Magalhaes MO, Marques AP. Comparison of the effects of low-level laser and pulsed and continuous ultrasound on pain and physical disability in chronic non-specific low back pain: a randomized controlled clinical trial. Adv Rheumatol. 2019 Dec 17;59(1):57. doi: 10.1186/s42358-019-0099-z.
citation: de Resende Guimaraes MFB, Rodrigues CEM, Gomes KWP, Machado CJ, Brenol CV, Krampe SF, de Andrade NPB, Kakehasi AM. High prevalence of obesity in rheumatoid arthritis patients: association with disease activity, hypertension, dyslipidemia and diabetes, a multi-center study. Adv Rheumatol. 2019 Oct 16;59(1):44. doi: 10.1186/s42358-019-0089-1.
Clinical trial NCT04080596: DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin
Official title: A Single Dose, Open Label, Drug-drug Interaction Study to Investigate the Pharmacokinetics, Pharmadynamics and Safety of HMS5552 Administered Alone or in Combination With Itraconazole in Patients With Type 2 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Drug Interaction
Lead sponsor: Hua Medicine Limited
Sponsor class: INDUSTRY
First posted: 2019-09-06
Enrollment: 18
Sex: ALL
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the impact of itraconzaole on the pharmacokinetics of Dorzagliatin.


Eligibility criteria: Inclusion Criteria:

* Age 30-65
* Body weight ≥ 50 kg
* BMI ≥ 19.0 kg/m2 and ≤ 30.0 kg/m2
* HbA1c ≥ 7% and ≤ 10.5%
* FPG ≥ 7.5 mmol/L and ≤ 13.3 mmol/L

Exclusion Criteria:

* T1DM
* Use of prescription or OTC medications, and herbal within 14 days prior to dosing
* Blood donation
* Any surgery or treatment that may impact the ADME of the drug

Primary outcomes:
measure: Cmax
timeFrame: up to 96 hours
measure: AUClast
timeFrame: up to 96 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Changchun
country: China
facility: The 2nd Hospital of Jilin University
state: Jilin
Study officials:
References:
Clinical trial NCT04344496: East Asian Breast Cancer Genome Atlas and Recurrence Risk Prediction
Official title: The Cancer Genome Atlas and Recurrence Risk Prediction of East Asian Breast Cancer: a Multicenter Collaborative Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Breast Cancer
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2020-04-14
Enrollment: 2000
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Stage I, II, III or IV Breast Cancer

Brief summary: This project aims to establish the cancer genome atlas and the platform of recurrence risk prediction specific for East Asian breast cancer patients. The study was planned to collect blood sample, fresh tumor tissue, and paraffin embedded tumor tissue from 2000 patients. Aims to identify unique genetic alterations in Asian tumors, to identify the susceptible genes for breast carcinogenesis in East Asia, and to establish the new platform for accurate prediction of recurrence. The investigator will explore the association of patient outcomes with the genetic alterations from the cancer atlas of East Asian breast tumors.


Eligibility criteria: Inclusion Criteria:

* 1. Aged more than 20-year-old at the time of informed consent.
* 2. An unconfirmed breast tumor, or have histologically confirmed invasive breast cancer.
* 3. Have radiological or objective evidence of breast tumor size ≥1 cm.
* 4. Be able to comply with study procedures to collect the clinical medical information, blood sample, fresh tumor tissue, and 12 sections of paraffin embedded tumor tissue.
* 5. Be able to sign an informed consent.

Exclusion Criteria:

* 1. Have histologically confirmed ductal carcinoma in situ (DCIS).
* 2. Stage I, II or III breast cancer patients who have received neoadjuvant treatments, including chemotherapy, hormonal therapy, or targeted therapy.
* 3. Stage IV or metastatic breast cancer patients who have received chemotherapy.

Primary outcomes:
measure: Prevalence of unique genetic alterations
timeFrame: 3 years
Secondary outcomes:
measure: Recurrence rate
timeFrame: 10 years
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Yen-Shen Lu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05518396: Prospective Validation of the CoDE-HF Algorithm for the Diagnosis of Acute Heart Failure
Official title: Prospective Validation of the CoDE-HF Algorithm for the Diagnosis of Acute Heart Failure
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Acute Heart Failure
Diagnosis
Keywords: Artificial Intelligence
Lead sponsor: University of Edinburgh
Sponsor class: OTHER
Collaborators: name: NHS Lothian
First posted: 2022-08-26
Enrollment: 3808
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All consecutive patients presenting to the Emergency Department with acute breathlessness will be included in this study

Brief summary: Acute heart failure is a life-threatening condition where the heart is suddenly unable to pump blood around the body. It can be challenging to diagnose because the symptoms often mimic other conditions. Previous studies have showed that delays in making the correct diagnosis result in worse outcomes. We therefore developed a decision-support tool called CoDE-HF that uses a computer algorithm to combine levels of a blood test called NT-proBNP with patient factors to calculate the probability of acute heart failure for an individual.

In this project, we wish to evaluate the performance of CoDE-HF in approximately 2,000 patients attending the Emergency Department with suspected acute heart failure. We will store surplus material from their blood tests to measure NT-proBNP and link information from their electronic health records with other routinely collected medical information in regional and national databases in order to evaluate this algorithm.


Eligibility criteria: Inclusion Criteria:

* Patients presenting to the Emergency Department with acute breathlessness

Primary outcomes:
measure: Adjudicated diagnosis of acute heart failure
timeFrame: At index presentation
Secondary outcomes:
measure: Subsequent hospitalisation with heart failure
timeFrame: 3 months
measure: All-cause death
timeFrame: 3 months
Other outcomes:
Locations:
city: Edinburgh
country: United Kingdom
facility: Centre for Cardiovascular Science, University of Edinburgh
Study officials:
References:
citation: Lee KK, Doudesis D, Anwar M, Astengo F, Chenevier-Gobeaux C, Claessens YE, Wussler D, Kozhuharov N, Strebel I, Sabti Z, deFilippi C, Seliger S, Moe G, Fernando C, Bayes-Genis A, van Kimmenade RRJ, Pinto Y, Gaggin HK, Wiemer JC, Mockel M, Rutten JHW, van den Meiracker AH, Gargani L, Pugliese NR, Pemberton C, Ibrahim I, Gegenhuber A, Mueller T, Neumaier M, Behnes M, Akin I, Bombelli M, Grassi G, Nazerian P, Albano G, Bahrmann P, Newby DE, Japp AG, Tsanas A, Shah ASV, Richards AM, McMurray JJV, Mueller C, Januzzi JL, Mills NL; CoDE-HF investigators. Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. BMJ. 2022 Jun 13;377:e068424. doi: 10.1136/bmj-2021-068424.
Clinical trial NCT01046396: Tolerability Comparison of Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin
Official title: Split-Face Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Skin Manifestations
Lead sponsor: Galderma R&D
Sponsor class: INDUSTRY
First posted: 2010-01-12
Enrollment: 69
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the tolerability of Differin® (adapalene) Cream, 0.1% to Differin® Lotion, 0.1% in subjects with healthy skin treated once a day for three (3) weeks.


Eligibility criteria: Inclusion Criteria:

* Males or females aged 18 years and older
* Subjects with healthy skin as determined by the clinical grader

Exclusion Criteria:

* Subjects with a degree of skin pigmentation that interferes with the reading of skin reactions.
* Subjects with a condition or who are in a situation, which in the investigator's opinion may put the subject at risk, may confound study results, or may interfere with the subject's participation in the study.
* Subjects with known allergy to one of the components of the study drugs (refer to the package insert for Differin® Cream 0.1% and the investigator's brochure for Differin® Lotion 0.1%).
* Subjects who have participated in another investigational drug or device research study within 30 days of enrollment.
* Subjects with a washout period for topical treatment on the treated area less than 1 week for corticosteroids and/or 4 weeks for retinoids.
* Subjects with a washout period for systemic treatment less than 1 week for medications that may increase photosensitivity and/or 4 weeks for corticosteroids and/or 6 months for retinoids.
* Subjects with current sunburn, eczema, atopic dermatitis, perioral dermatitis or rosacea on the area to be treated.
* Subjects who foresee unprotected and intense UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.)

Primary outcomes:
measure: Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3.
timeFrame: baseline to week 3
Secondary outcomes:
measure: 6 Question Subject Cosmetic Acceptability Questionnaire at Week 3
timeFrame: week 3
Other outcomes:
Locations:
city: Colorado Springs
country: United States
facility: Thomas J. Stephens & Associates, Inc.
state: Colorado
Study officials:
affiliation: Galderma R&D
name: Ronald W Gottschalk, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03652896: Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma
Official title: Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hepatocellular Carcinoma by BCLC Stage
Keywords: hepatocellular carcinoma
anatomical liver resection
Lead sponsor: Huazhong University of Science and Technology
Sponsor class: OTHER
First posted: 2018-08-29
Enrollment: 60
Sex: ALL
Minimum age (years): 17
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Anatomical liver resection was widely accepted as first line curative therapy for hepatocellular carcinoma. However, number of retrospective clinical studies showed no priority of anatomical resection for hepatocellular, compared with non-anatomical resection.

Surgical resection margin is a essential factor that may affect tumor prognosis. It is controversial whether adequate liver resection margin is associated with improved survival outcome in patients with hepatocellular.

There was few prospective clinical trial to investigate whether anatomical liver resection is superior to non-anatomical resection or liver resection with adequate margin is superior to that with inadequate margin. This prospective clinical trial aims at fix these issues.

Detailed description: In the anatomical liver resection group, liver segmentectomy or lobectomy is performed to insure curative resection (R0 resection). The region of liver resected is based on the anatomy or portal vein and hepatic vein. The liver pedicle of the tumor located lobe is exposed and dissected, which is principle to perform anatomical liver resection.

In the non-anatomical liver resection group, the liver parenchyma transection is around 0-2 cm from the tumor margin, according to tumor size and location.

Eligibility criteria: Inclusion Criteria:

* patients diagnosed with hepatocellular carcinoma of BCLC stage A
* liver function Child-pugh A
* normal indocyanine green retention rate
* adequate liver remnant

Exclusion Criteria:

* age less than 17 y or older than 65 y
* unresectable liver cancer
* intraoperative ablation
* contraindication for liver resection
* preoperative treatment for hepatocellular
* active hepatitis
* pregnant
* multi-original tumors
* mixed liver cancer (hepatocellular carcinoma and cholangiocellular carcinoma)
* tumor recurrence

Primary outcomes:
measure: prognosis
timeFrame: 5 years
Secondary outcomes:
measure: postoperative recovery
timeFrame: 30 days postoperatively
measure: hospital stay
timeFrame: 60 days postoperatively
Other outcomes:
measure: surgery duration
timeFrame: 24 hours
measure: volume of bleeding
timeFrame: 24 hours
measure: volume of transfusion
timeFrame: 24 hours
Locations:
city: Wuhan
country: China
facility: Hepatic Surgery Center of Tongji Hospital
state: Hubei
Study officials:
affiliation: Huazhong University of Science and Technology
name: Xiaoping Chen, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06902116: Comparison of Outcome of Three Days Bowel Preparation vs No Bowel Preparation in Patients of Colostomy Reversal
Official title: Comparison of Outcome of Three Days Bowel Preparation vs No Bowel Preparation in Patients of Colostomy Reversal
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Colostomy - Stoma
Bowel Preparation
BOWEL ANASTOMOSIS
Lead sponsor: University of Child Health Sciences and Children's Hospital, Lahore
Sponsor class: OTHER
First posted: 2025-03-30
Enrollment: 80
Sex: ALL
Minimum age (years): 1
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this trial is to compare the outcomes of colostomy reversal with three days bowel preparation with no bowel preparation in terms of anastomotic leakage, surgical site infection and hospital stay.

The important question this trial aims to answer is:

1. is there any difference in outcomes after colostomy reversal with three days gut preparation pre-operatively vs no gut preparation?

This prospective Randomized Controlled trial will include children with colostomy divided into two groups:

Group A: No Mechanical Bowel Preparation Group B: 3 Days Mechanical Bowel Preparation Participants of Group A will be admitted 1 day prior to surgery date as they require no special preparation before surgery. They will be made Nil per oral 6 hours prior to surgery. Group B participants will be admitted 3 days prior to surgery. These participants will be restricted to fiber rich diet and milk 72 hours prior to surgery. They will be shifted to clear liquids 24 hours prior to surgery. Normal saline enema will be given 8 hourly through the stoma as well as per rectally by the trained person.

Comparative outcomes will be:

1. Anastomotic leakage
2. Hospital Stay
3. Wound infection


Eligibility criteria: Inclusion Criteria:

* Children with colostomy between 1-15 years of age

Exclusion Criteria:

* Malnourished
* Previous history of colostomy site anastomotic leakage

Primary outcomes:
measure: Anastomotic Leakage
timeFrame: 5-10 days post operatively.
measure: Wound infection
timeFrame: At 7 days after surgery and then at 30 days after surgery.
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: University of Child Health Sciences, The Children's Hospital
state: Punjab
Study officials:
References:
citation: Cavusoglu YH, Karaman A, Afsarlar CE, Karaman I, Erdogan D, Ozguner IF. Ostomy Closures in Children: Variations in Perioperative Care Do Not Change the Outcome. Indian J Surg. 2015 Dec;77(Suppl 3):1131-6. doi: 10.1007/s12262-015-1212-0. Epub 2015 Jan 19.
citation: Ares GJ, Helenowski I, Hunter CJ, Madonna M, Reynolds M, Lautz T. Effect of preadmission bowel preparation on outcomes of elective colorectal procedures in young children. J Pediatr Surg. 2018 Apr;53(4):704-707. doi: 10.1016/j.jpedsurg.2017.03.060. Epub 2017 Mar 30.
Clinical trial NCT01009216: A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid
Official title: A Study to Evaluate the Cerebrospinal Fluid Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-384 in Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Pharmacokinetics
Pharmacology
Drug Safety
Phase 1 Clinical Trials
Lead sponsor: Abbott
Sponsor class: INDUSTRY
First posted: 2009-11-06
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objectives of this study are to assess the cerebral spinal fluid (CSF) pharmacokinetics and the plasma/CSF pharmacokinetic/pharmacodynamic relationship of ABT-384 in healthy male volunteers.


Eligibility criteria: Inclusion Criteria:

* Age is between 18 and 55 years
* Judged to be in a condition of general good health based on the results of medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG

Exclusion Criteria:

* Use of protocol-prohibited medications within 2 weeks prior to study drug administration.
* Positive urine drug screen for non-prescribed drugs of abuse including alcohol.
* Receipt of any drug depot by injection within 30 days prior to study drug administration.
* Receipt of any investigational product within 6 weeks prior to study drug administration.
* History of significant sensitivity or allergy to any drug.
* History of drug or alcohol abuse.
* Positive test result for HAV, HBsAg, HCV or HIV.
* Donation or loss of 550 mL or more blood volume or receipt of any blood product within 3 months prior to study drug administration.
* Contraindication for lumbar puncture (e.g., lumbar scoliosis, coagulopathy, infected skin at puncture site)
* Current enrollment in another clinical study.

Primary outcomes:
measure: Safety and Tolerability Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical and brief neurological examinations)
timeFrame: Days -1 through 9
measure: Assess Pharmacokinetics (i.e., ABT-384 and possible metabolite levels) and Pharmacodynamics (i.e., biomarkers of drug effect)
timeFrame: Days 1, 4 through 9
Secondary outcomes:
Other outcomes:
Locations:
city: Glendale
country: United States
facility: Site Reference ID/Investigator# 23882
state: California
Study officials:
References: